Cite this article:
The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods. Cite this article:
There is continued debate as to whether cemented or cementless implants should be utilized in particular cases based upon chronological age. This debate has been rekindled in the UK and other countries by directives mandating certain forms of acetabular and femoral component fixation based exclusively on the chronological age of the patient. This editorial focuses on the literature-based arguments to support the use of cementless total hip arthroplasty (THA), while addressing potential concerns surrounding safety and cost-effectiveness. Cite this article:
Health economic evaluations potentially provide
valuable information to clinicians, health care administrators,
and policy makers regarding the financial implications of decisions
about the care of patients. The highest quality research should
be used to inform decisions that have direct impact on the access
to care and the outcome of treatment. However, economic analyses
are often complex and use research methods which are relatively unfamiliar
to clinicians. Furthermore, health economic data have substantial
national, regional, and institutional variability, which can limit
the external validity of the results of a study. Therefore, minimum
guidelines that aim to standardise the quality and transparency
of reporting health economic research have been developed, and instruments
are available to assist in the assessment of its quality and the
interpretation of results. The purpose of this editorial is to discuss the principal types
of health economic studies, to review the most common instruments
for judging the quality of these studies and to describe current
reporting guidelines. Recommendations for the submission of these
types of studies to Cite this article:
